Seeking Alpha

Pharmacyclics (PCYC) +3.7% premarket after signing an agreement with Novo Nordisk (NVO) that...

Pharmacyclics (PCYC) +3.7% premarket after signing an agreement with Novo Nordisk (NVO) that gives the Danish insulin producer rights to certain uses of its Factor VIIa molecule inhibitor. PCYC expects to receive $5M up front, as much as $55M in milestone payments, plus royalties on sales of NVO products that use the drug.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|